Status:
TERMINATED
The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension
Lead Sponsor:
Actelion
Conditions:
Pulmonary Hypertension
Eligibility:
All Genders
12-85 years
Phase:
PHASE3
Brief Summary
The purpose of this multi-center international trial is to evaluate the safety and effectiveness of adding iloprost or placebo (an inactive substance that contains no active study drug) to sildenafil ...
Eligibility Criteria
Inclusion
- Aged 12-85 years; of either gender.
- Confirmed PAH due to idiopathic pulmonary arterial hypertension (IPAH) or familial pulmonary arterial hypertension (FPAH).
- 6-minute walk distance (6-MWD) between 100-450 meters at screening.
- On a stable dose of sildenafil, with or without bosentan.
Exclusion
- Any treatment for PAH with prostacyclins, prostacyclin analogues, endothelin-1 antagonists, or phosphodiesterase-5 (PDE-5) inhibitors other than sildenafil within the past 12 weeks.
- Pulmonary hypertension due to conditions other than those stated in inclusion criteria.
- Additional PAH medications added within the past 12 weeks.
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT00302211
Start Date
February 1 2006
End Date
July 1 2008
Last Update
February 4 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.